νΌλμ€ν 리λ
νΌλμ€ν 리λλ 5-μν νμν¨μμ κ²½μμ μ΄κ³ νΉμ΄μ μΈ μ΅μ μ λ‘ μμ©νλ ν©μ± 4-μμμ€ν λ‘μ΄λ νν©λ¬Όμ λλ€. μμνμμλ μ£Όλ‘ μ€μ±νλμ§ μμ μμ»· κ°μ **μμ± μ 립μ λΉλμ¦(BPH)**μ λ΄κ³Όμ κ΄λ¦¬μ μ¬μ©λ©λλ€. νΉν λ²μμ© μ’ κ²¬μκ² μμ΄ μμ λ₯λ ₯μ΄λ νμ€ ν μ€ν μ€ν λ‘ μμΉμ ν° μν₯μ μ£Όμ§ μμΌλ©΄μ μ 립μ ν¬κΈ°λ₯Ό μ€μ¬μ£Όλ―λ‘, μΈκ³Όμ κ±°μΈλ₯Ό λ체ν μ μλ λ§€μ° ν¨κ³Όμ μΈ λμμ μ 곡ν©λλ€. λν, νλΏμ **λΆμ μ§ν**μ λν 보쑰 μλ²μΌλ‘ νκ° μΈ(off-label)λ‘ μ¬μ©λλ©°, μμ»· νλΏμμ μλλ‘κ²μ μν΄ μ λ°λλ μμ μ¦μ(μ: μ 립μ λΉλ λ° μλ νμ)μ κ΄λ¦¬νλ λ° λμμ μ€λλ€.
μμ© κΈ°μ : Finasteride specifically and totally inhibits the intracellular enzyme **5-alpha-reductase** (predominantly Type II). * **Pathway**: Testosterone β (via **5-alpha-reductase**) β **Dihydrotestosterone (DHT)** DHT is a highly potent androgen and is the primary hormone responsible for the development and enlargement of the prostate gland. By blocking this conversion, finasteride significantly reduces DHT concentrations in the prostate, liver, and skin. This leads to prostatic involution and a reduction in clinical signs of BPH. Because it does not directly block testosterone or its receptors, normal testosterone-dependent functions (such as spermatogenesis and libido) are largely preserved.
λλ¬Ό μ’ λ³ μ©λ
- Adjunctive treatment of adrenal disease Β· 5 mg (total dose) Β· PO Β· once daily Β· tablet
- Benign prostatic hyperplasia Β· 0.1-0.5 mg/kg Β· PO Β· once daily Β· for a 10-50 kg dog, one 5 mg tablet daily
- Benign prostatic hyperplasia Β· <15 kg: 1.5 mg (approx. 1/3 of a 5 mg tablet); 15-30 kg: 2.5 mg (1/2 tablet); >30 kg: 5 mg (one tablet) Β· PO Β· daily
- Benign prostatic hypertrophy Β· 5 mg per dog Β· PO Β· q24h Β· Extended treatment course (<8 weeks) may be required for full efficacy Β· Alternative to castration. Use when delmadinone or osaterone are not appropriate.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Hypersensitivity to finasteride
- Sexually developing animals
- Females (especially pregnant females)
- Sexually-developing dogs
- Breeding dogs (due to secretion in semen and teratogenic potential)
μ΄μλ°μ
- Decreased libido
- Decreased ejaculate volume
- Impotence (rare/mild)
- Secreted into semen
- Causes fetal anomalies (teratogenic)
μ½λ¬Ό μνΈμμ©
- Anticholinergic drugs Β· May precipitate or aggravate urinary retention thereby negating the effects of the drug when used for BPH
λͺ¨λν°λ§
- Prostate exam (to evaluate efficacy and reduction in size)
- Prostate size (via palpation or ultrasound)
- Resolution of clinical signs (e.g., tenesmus, dysuria, hematuria)
κ³Όμ©λ
Limited information is available regarding acute toxicity. Mild **gastrointestinal effects** (such as vomiting or diarrhea) may be noted in the event of an overdose. Supportive care is recommended.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.